ReviewEuropean cardiology2021
The Role of C-reactive Protein in Patient Risk Stratification and Treatment.
Review in European cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Dose-dependent effects of omega-3 polyunsaturated fatty acids on C-reactive protein concentrations in cardiometabolic disorders: a dose-response meta-analysis of randomized clinical trials.Inflammopharmacology · 2025Pooled it
- Cardiometabolic Biomarkers for Disease Severity Prediction in Metabolic Dysfunction-Associated Steatotic Liver Disease.The Kaohsiung journal of medical sciences · 2026Article
- The social ambivalence and disease model: Childhood trauma as an antecedent factor linking spousal ambivalence to inflammation.Health psychology : official journal of the Division of Health Psychology, American Psychological Association · 2026Article
- Residual inflammatory risk post STEMI: high prevalence despite LDL-C control and association with other secondary prevention targets.Frontiers in cardiovascular medicine · 2026Article
- Inflammation and lipid-related determinants in coronary atherosclerosis: mechanisms, biomarkers, and therapeutic implications.Frontiers in cardiovascular medicine · 2026Review
- Post-PCI Inflammation and Diastolic Dysfunction in Patients with Metabolic Risk Factors: A Retrospective Observational Study.Medicina (Kaunas, Lithuania) · 2025Observational
- Predictive value of remnant cholesterol inflammatory index for stroke risk: Evidence from the China health and Retirement Longitudinal study.Journal of advanced research · 2025Article
- Novel cardiac biomarkers and multiple-marker approach in the early detection, prognosis, and risk stratification of cardiac diseases.World journal of cardiology · 2025Review
- C-reactive Protein and Biliary Complications as Independent Predictors of Hospital Stay in Acute Cholecystitis.Cureus · 2025Article
- Soluble Suppression of Tumorigenicity 2 (sST2) as a Diagnostic and Prognostic Marker in Acute Heart Failure and Sepsis: A Comparative Analysis.Diagnostics (Basel, Switzerland) · 2025Article
- Beyond Cholesterol: Emerging Risk Factors in Atherosclerosis.Journal of clinical medicine · 2025Review
- Article
- Pentraxin-3 and Outcomes in CKD: A Systematic Review and Meta-analysis.Kidney medicine · 2024Article
- J-shaped association between LDL cholesterol and cardiovascular events: A longitudinal primary prevention cohort of over 2.4 million people nationwide.Journal of advanced research · 2024Article
- Potential Roles of microRNAs for Assessing Cardiovascular Risk in Pre-Eclampsia-Exposed Postpartum Women and Offspring.International journal of molecular sciences · 2023Review
- Biomarkers to monitor the prognosis, disease severity, and treatment efficacy in coronary artery disease.Expert review of cardiovascular therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is a chronic inflammatory disease. Several circulating inflammatory markers have been proposed for clinical use due to their ability to predict future cardiovascular events and may be useful for identifying people at high risk who might benefit from specific treatment to reduce this risk. Moreover, the identification of new therapeutic targets will allow the development of drugs that can help reduce the high residual risk of recurrence of cardiovascular events in patients with coronary artery disease. The clinical benefits of reducing recurrent major cardiovascular events recently shown by canakinumab and colchicine have renewed the cardiology community's interest in inflammation as an aetiopathogenic mechanism for atherosclerosis. This review explores the use of C-reactive protein, which is the most frequently studied biomarker in this context; the concept of residual risk in primary and secondary cardiovascular prevention; and the current recommendations in international guidelines regarding the role of this inflammatory biomarker in cardiovascular risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.